{"id":"placebo-of-mci-196","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation is inert and produces no pharmacological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of the active drug MCI-196 relative to no treatment effect.","oneSentence":"This is a placebo control arm and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00542386","phase":"PHASE3","title":"A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-12","conditions":"Chronic Kidney Disease, Dialysis, Hyperphosphatemia","enrollment":642},{"nctId":"NCT00506441","phase":"PHASE3","title":"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-09","conditions":"Chronic Kidney Disease, Dialysis, Hyperphosphatemia","enrollment":245},{"nctId":"NCT00416520","phase":"PHASE3","title":"A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-06","conditions":"Chronic Kidney Disease, Hyperphosphatemia","enrollment":336},{"nctId":"NCT00858637","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-03","conditions":"Chronic Kidney Disease","enrollment":260},{"nctId":"NCT00497198","phase":"PHASE2","title":"Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":183},{"nctId":"NCT00451295","phase":"PHASE3","title":"A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-05","conditions":"Chronic Kidney Disease, Dialysis, Hyperphosphatemia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of MCI-196","genericName":"Placebo of MCI-196","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}